-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Endonovo Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2022.
- Endonovo Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2023 was -$473K, a 4.83% increase year-over-year.
- Endonovo Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2023 was -$2.62M, a 17.1% increase year-over-year.
- Endonovo Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$3.26M, a 46.6% decline from 2021.
- Endonovo Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$2.23M, a 23.5% increase from 2020.
- Endonovo Therapeutics, Inc. annual Operating Income (Loss) for 2020 was -$2.91M, a 23.5% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)